JP2010507567A5 - - Google Patents

Download PDF

Info

Publication number
JP2010507567A5
JP2010507567A5 JP2009523960A JP2009523960A JP2010507567A5 JP 2010507567 A5 JP2010507567 A5 JP 2010507567A5 JP 2009523960 A JP2009523960 A JP 2009523960A JP 2009523960 A JP2009523960 A JP 2009523960A JP 2010507567 A5 JP2010507567 A5 JP 2010507567A5
Authority
JP
Japan
Prior art keywords
use according
pharmaceutically acceptable
cxcr4 inhibitor
acceptable salt
cxcr2 agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009523960A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010507567A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/075376 external-priority patent/WO2008019371A1/en
Publication of JP2010507567A publication Critical patent/JP2010507567A/ja
Publication of JP2010507567A5 publication Critical patent/JP2010507567A5/ja
Withdrawn legal-status Critical Current

Links

JP2009523960A 2006-08-07 2007-08-07 併用療法 Withdrawn JP2010507567A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83640906P 2006-08-07 2006-08-07
PCT/US2007/075376 WO2008019371A1 (en) 2006-08-07 2007-08-07 Combination therapy

Publications (2)

Publication Number Publication Date
JP2010507567A JP2010507567A (ja) 2010-03-11
JP2010507567A5 true JP2010507567A5 (enExample) 2010-09-30

Family

ID=39033325

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009523960A Withdrawn JP2010507567A (ja) 2006-08-07 2007-08-07 併用療法

Country Status (12)

Country Link
US (1) US20100178271A1 (enExample)
EP (1) EP2056853A1 (enExample)
JP (1) JP2010507567A (enExample)
CN (1) CN101500595A (enExample)
AR (1) AR062271A1 (enExample)
AU (1) AU2007281677A1 (enExample)
BR (1) BRPI0715393A2 (enExample)
CA (1) CA2659337A1 (enExample)
IL (1) IL196559A0 (enExample)
MX (1) MX2009001445A (enExample)
RU (1) RU2009108289A (enExample)
WO (1) WO2008019371A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG177959A1 (en) * 2007-01-09 2012-02-28 Cleveland Biolabs Inc Methods for increasing and mobilizing hematopoietic stem cells
WO2009108360A2 (en) * 2008-02-29 2009-09-03 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of post-radiation tumor growth
US10813917B2 (en) * 2009-12-11 2020-10-27 Medregen, Llc Treatment methods utilizing stem cell mobilizers and immunosuppressive agents
EP2549992B1 (en) 2010-03-23 2019-08-14 The Johns Hopkins University Methods of treatment using stem cell mobilizers
EP2384759A1 (en) 2010-05-06 2011-11-09 Suomen Punainen Risti Veripalvelu Sulphated hyaluronic acid in combination with G-CSF for use in mobilising blood stem cells
US8546353B2 (en) 2010-05-06 2013-10-01 Glykos Finland Oy Compounds and combinations
ES2370986B1 (es) * 2010-06-08 2012-11-16 Institut Quimic De Sarria Cets Nuevos inhibidores de cxcr4 como agentes anti-vih
WO2012047339A2 (en) 2010-06-28 2012-04-12 The General Hospital Corporation Anti-cxcr4 as a sensitizer to cancer therapeutics
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
ES3005233T3 (en) 2010-10-01 2025-03-14 Modernatx Inc Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
US9682078B2 (en) 2011-03-18 2017-06-20 University Of Virginia Patent Foundation Compositions and methods for tissue engineering and cell based therapies
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US20150030561A1 (en) 2011-05-16 2015-01-29 Genzyme Corp. Use of CXCR4 Antagonists
US9763980B2 (en) 2011-06-16 2017-09-19 Children's Medical Center Corporation Combined chemical modification of sphingosine-1-phosphate (S1P) and CXCR4 signalling pathways for hematopoietic stem cell (HSC) mobilization and engraftment
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2763701B1 (en) 2011-10-03 2018-12-19 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
JP2015501844A (ja) 2011-12-16 2015-01-19 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151663A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of membrane proteins
ES2921623T3 (es) 2012-11-26 2022-08-30 Modernatx Inc ARN modificado terminalmente
KR20160023638A (ko) * 2013-02-28 2016-03-03 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 줄기세포를 이동하기 위한 방법 및 조성물
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
CA3026154A1 (en) 2015-06-03 2016-12-08 The University Of Queensland Mobilizing agents and uses therefor
WO2017106630A1 (en) 2015-12-18 2017-06-22 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
CN110035702A (zh) * 2016-10-24 2019-07-19 耶鲁大学 穿刺装置
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
EP3703714A1 (en) 2017-11-03 2020-09-09 Roemer & Heigl GmbH Extraction of stem cells from bone marrow niches
CN111712262A (zh) * 2017-12-06 2020-09-25 美真达治疗公司 用于动员造血干细胞和祖细胞的给药方案
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US10058573B1 (en) 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells
EP4146797A1 (en) 2020-05-06 2023-03-15 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
WO2022101359A1 (en) 2020-11-12 2022-05-19 Roemer & Heigl Gmbh Reversible release of stem cells from bone marrow niches
WO2025224720A1 (en) 2024-04-24 2025-10-30 Biolinerx Ltd. Methods of selecting treatment regimen against solid tumors

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5021409A (en) * 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
US6001826A (en) * 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
GB9126677D0 (en) * 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
ES2210255T3 (es) * 1993-06-08 2004-07-01 Smithkline Beecham Corporation Metodos para mejorar la actividad biologica de quimiocinas.
US6447766B1 (en) * 1993-06-08 2002-09-10 Smithkline Beecham Corporation Method of mobilizing hematopoietic stem cells
DE4320478B4 (de) * 1993-06-21 2007-11-15 Robert Bosch Gmbh Fahrstabilitätsregler
GB9400411D0 (en) * 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
GB9511357D0 (en) * 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US6506770B1 (en) * 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
US6713052B1 (en) * 1995-10-24 2004-03-30 Human Genome Sciences, Inc. Method of mobilizing stem cells with chemokine β-8
US6365583B1 (en) * 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
US6750348B1 (en) * 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
WO2001044229A1 (en) * 1999-12-17 2001-06-21 Anormed Inc. Chemokine receptor binding heterocyclic compounds
US6864265B2 (en) * 2000-09-15 2005-03-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
DK1317451T3 (da) * 2000-09-15 2006-12-18 Anormed Inc Kemokinreceptorbindende heterocykliske forbindelser
MXPA03002772A (es) * 2000-09-29 2003-07-28 Anormed Inc Procedimiento para la preparacion de poliaminas ciclicas que contienen nitrogeno en el anillo n-1 protegidos y productos de los mismos.
US6853731B1 (en) * 2000-09-30 2005-02-08 Keen Personal Technologies, Inc. Digital video recorder employing a unique ID to interlock with encrypted video programs stored on a storage device
EP1385865A4 (en) * 2001-04-03 2005-05-25 Applera Corp ISOLATED HUMAN KINASEPROTEINS, NUCLEIC ACID MOLECULES CODING FOR HUMAN KINASEPROTEINS AND THEIR USES
JP5137288B2 (ja) * 2001-07-31 2013-02-06 アノーメッド インコーポレイティド 前駆／幹細胞を動員する方法
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
EP1451297A4 (en) * 2001-12-07 2006-06-28 Toolgen Inc PHENOTYPIC SCANNING OF CHIMERIC PROTEINS
CA2520259A1 (en) * 2003-04-11 2004-10-28 Anormed Inc. Cxcr4 chemokine receptor binding compounds
CA2517077C (en) * 2003-04-22 2013-03-12 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
WO2005059107A2 (en) * 2003-12-11 2005-06-30 Anormed Inc. Chemokine receptor binding compounds

Similar Documents

Publication Publication Date Title
JP2009545620A5 (enExample)
RU2009108289A (ru) Комбинированная терапия
Pusic et al. Update on clinical experience with AMD3100, an SDF-1/CXCL12–CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells
RU2009107030A (ru) Комбинированная терапия
EP4353818A3 (en) Compositions, articles of manufacture and methods related to dosing in cell therapy
JP2012526850A5 (enExample)
CA2560058A1 (en) A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
JP2021059579A (ja) 癌を処置するための医薬組合せ
JP2007529532A5 (enExample)
KR102854375B1 (ko) 혈액 암을 위한 조합 치료법
CN106822905B (zh) 含Survivin抑制剂和IRE1抑制剂的药物及用途
JP2023541430A5 (enExample)
MX2010010026A (es) Agente para tratar enfermedad.
JP2019503365A5 (enExample)
JP2012067116A5 (enExample)
NZ707377A (en) Combination therapy methods for treating proliferative diseases
MX358491B (es) Una composicion farmacéutica para tratar cáncer, que comprende un conjugado de interferón alfa.
JP2009545600A5 (enExample)
JP2021046446A (ja) グルココルチコイド及びｅｄｏ−ｓ１０１を含む組合せ
JP2012517449A5 (enExample)
MA56827B2 (fr) Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine
JP2013541583A5 (enExample)
WO2009043481A3 (en) Use of adrenomedullin 13-52 and optionally retrocyclin-1 as a therapeutic agent for the treatment of hcmv infections
JP2009506054A5 (enExample)
WO2015126816A1 (en) Combination therapy for hematological malignancies